menu
    • menu
    [{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"||pH","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dyve Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"DYV700","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Lotion","sponsorNew":"Dyve Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dyve Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"DYV-700","moa":"Undisclosed","graph1":"Rheumatology","graph2":"Phase II","graph3":"Dyve Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyve Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dyve Biosciences \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Dyve Biosciences

    Menu

    Dyve Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dyve Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dyve Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYV702,Colchicine

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dyve Biosciences Announces Phase 2 TARGETS Study of DYV702 for Pain Associated with Acute Gout Flares Showcase...

                            Details : Topical application of DYV702 significantly reduced pain intensity and duration of acute gout flare with higher overall response rates, faster time to resolution, improvements in physical function and reduction in rescue medication use.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : DYV702,Colchicine

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dyve Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dyve Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYV700

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dyve Biosciences Announces First Patient Enrolled in TARGETS Study for Treatment of Acute Gout

                            Details : Dyve’s Phase 2 trial is designed to enroll 300 subjects across 20 trial centers in the U.S.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 20, 2020

                            Lead Product(s) : DYV700

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dyve Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Dyve Biosciences

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYV-700

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

                            Details : DYV-700 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Gout.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 17, 2019

                            Lead Product(s) : DYV-700

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth